Roche’s Actemra IV (tocilizumab) Receives Health Canada Authorization for Additional Indication to Treat COVID-19
Shots:
- Health Canada has granted authorization for Actemra IV in hospitalized adult patients with COVID-19
- The approval was based on P-III results from the (RECOVERY) trial evaluating Actemra IV in the UK. Eligible patients (n=21 550) were given standard care before being randomly assigned to 0, 1, 2, or 3 additional COVID-19 treatments while Actemra is administered as a single IV infusion of 8mg/kg over 60min.
- The primary outcome was time to death through Day 28, 31% randomized to tocilizumab + usual care vs 35% to usual care alone died within 28 days; median time to hospital discharge was 19 vs >28 days; patients who required mechanical ventilation or died by Day 28 (35% vs 42%)
Ref: Newswire | Image: Roche
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
